Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma

SM Ansell; SM Geyer; PJ Kurtin; KM Rowland; PJ Flynn; RF Morton

doi:10.4081/hmr.v1i8.298

Abstracts

3 June 2009

Vol. 1 No. 8 (2005)

https://doi.org/10.4081/hmr.v1i8.298

Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

239

Views

431

Downloads

Authors

SM Ansell

support@pagepress.org

SM Geyer

PJ Kurtin

KM Rowland

PJ Flynn

RF Morton

Mantle cell lymphoma (MCL) represents approximately 8% of cases of non-Hodgkin’s lymphoma (NHL) and is an incurable, aggressive B-cell malignancy. The disease usually presents in an advanced stage and commonly involves extranodal sites such as the gut, bone marrow, and peripheral blood. Most patients are older adults and there is a male predominance. The characteristic tumor cell immunophenotype is a population of CD20+, CD10-, CD5+, CD23- B-cells with monoclonal light chain expression on the cell surface.